Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study
dc.contributor.author | Schoenberg, Paige | |
dc.contributor.author | Edwards, O. Winslow | |
dc.contributor.author | Merrill, Leland | |
dc.contributor.author | Martinez, Cristian Acero | |
dc.contributor.author | Stephenson, Rob | |
dc.contributor.author | Sullivan, Patrick S. | |
dc.contributor.author | Jones, Jeb | |
dc.date.accessioned | 2023-04-04T17:41:47Z | |
dc.date.available | 2024-04-04 13:41:45 | en |
dc.date.available | 2023-04-04T17:41:47Z | |
dc.date.issued | 2023-03 | |
dc.identifier.citation | Schoenberg, Paige; Edwards, O. Winslow; Merrill, Leland; Martinez, Cristian Acero; Stephenson, Rob; Sullivan, Patrick S.; Jones, Jeb (2023). "Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study." Journal of the International AIDS Society 26(3): n/a-n/a. | |
dc.identifier.issn | 1758-2652 | |
dc.identifier.issn | 1758-2652 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/176073 | |
dc.description.abstract | IntroductionLong-acting injectable (LAI) pre-exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference for LAI versus oral PrEP has not been reported for sexual and gender minority (SGM) people in the southern United States, where the HIV epidemic is concentrated. Our goal was to assess willingness to use LAI PrEP and preference for oral versus LAI PrEP among SGM people in the southern United States and to assess differences in willingness by demographics and sexual behaviour.MethodsWe conducted an online, cross-sectional survey of SGM people aged 15–34 years in the southern United States (n = 583). Participants reported willingness to use LAI PrEP and preferences for LAI PrEP versus daily oral PrEP. We assessed bivariate associations and adjusted prevalence ratios for the LAI-PrEP-related outcomes and key demographic and behavioural characteristics.ResultsOverall, 68% of all participants (n = 393) reported being willing to use LAI PrEP that provides protection against HIV for 3 months. Of those, most (n = 320, 81%) indicated a preference for using LAI PrEP, compared to a daily oral pill or no preference. Willingness to use LAI PrEP was more common among transgender and non-binary participants and participants who engaged in condomless anal intercourse in the last 6 months. Hispanic participants were more likely and non-Hispanic Black participants were less likely to report willingness to use LAI PrEP compared to non-Hispanic White participants.ConclusionsWillingness to use LAI PrEP was high among SGM people in the southern United States, although there were some important differences in willingness based on demographic characteristics. Decreased willingness to use LAI PrEP among groups who are disproportionately affected by the HIV epidemic, such as non-Hispanic Black SGM people, could exacerbate existing disparities in HIV incidence. LAI PrEP is an acceptable option among SGM populations in the southern United States, but strategies will be needed to ensure equitable implementation. | |
dc.publisher | U.S. Food and Drug Administration | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | transgender people | |
dc.subject.other | sexual and gender minority populations | |
dc.subject.other | pre-exposure prophylaxis | |
dc.subject.other | HIV | |
dc.subject.other | injectable | |
dc.subject.other | men who have sex with men | |
dc.title | Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Microbiology and Immunology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/176073/1/jia226077.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/176073/2/jia226077_am.pdf | |
dc.identifier.doi | 10.1002/jia2.26077 | |
dc.identifier.source | Journal of the International AIDS Society | |
dc.identifier.citedreference | Muller CJ, MacLehose RF. Estimating predicted probabilities from logistic regression: different methods correspond to different target populations. Int J Epidemiol. 2014; 43 ( 3 ): 962 – 70. | |
dc.identifier.citedreference | FDA approves first injectable treatment for HIV pre-exposure prevention. U.S. Food and Drug Administration; 2021. | |
dc.identifier.citedreference | Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States –2021 update clinical practice guideline. 2021. Accessed April 18, 2022. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf | |
dc.identifier.citedreference | Wray TB, Chan PA, Kahler CW, Simpanen EM, Liu T, Mayer KH. Vulnerable periods: characterizing patterns of sexual risk and substance use during lapses in adherence to HIV pre-exposure prophylaxis among men who have sex with men. J Acquir Immune Defic Syndr. 2019; 80 ( 3 ): 276 – 83. | |
dc.identifier.citedreference | Landovitz RJ, Donnell D, Clement ME, Brett H, Leslie C, Lara C, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021; 385 ( 7 ): 595 – 608. | |
dc.identifier.citedreference | Levy ME, Agopian A, Magnus M, Anthony R, Jenevieve O, Michael K, et al. Is long-acting injectable cabotegravir likely to expand PrEP coverage among MSM in the District of Columbia? J Acquir Immune Defic Syndr. 2021; 86 ( 3 ): e80 – 2. | |
dc.identifier.citedreference | John SA, Whitfield THF, Rendina HJ, Parsons JT, Grov C. Will gay and bisexual men taking oral pre-exposure prophylaxis (PrEP) switch to long-acting injectable PrEP should it become available? AIDS Behav. 2018; 22 ( 4 ): 1184 – 89. | |
dc.identifier.citedreference | Golub SA, Meyers K, Enemchukwu C. Perspectives and recommendations from lesbian, gay, bisexual, transgender, and queer/questioning youth of color regarding engagement in biomedical HIV prevention. J Adolesc Health. 2020; 66 ( 3 ): 281 – 87. | |
dc.identifier.citedreference | Centers for Disease Control and Prevention. HIV surveillance report. 2020. Accessed July 6, 2022. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html | |
dc.identifier.citedreference | Centers for Disease Control and Prevention. HIV surveillance in urban and nonurban areas. 2018. Accessed March 26, 2021. https://www.cdc.gov/hiv/pdf/library/slidesets/cdc-hiv-surveillance-urban-nonurban-2018.pdf | |
dc.identifier.citedreference | Institute of Medicine (IOM). The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. National Academies Press; 2011. | |
dc.identifier.citedreference | Gengiah TN, Moosa A, Naidoo A, Mansoor LE. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2014; 36 ( 1 ): 70 – 85. | |
dc.identifier.citedreference | Stephenson R, Rogers E, Mansergh G, Hirshfield S, Sullivan P. Intimate partner violence and preferences for pre-exposure prophylaxis (PrEP) modes of delivery among a sample of gay, bisexual, and other men who have sex with men. AIDS Behav. 2022; 26 ( 7 ): 2425 – 34. | |
dc.identifier.citedreference | Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the U.S. AIDS Behav. 2016; 20 ( 7 ): 1390 – 9. | |
dc.identifier.citedreference | Waldorf B, Kim A. The Index of Relative Rurality (IRR): US county data for 2000 and 2010. 2018. | |
dc.identifier.citedreference | Waldorf BS. A continuous multi-dimensional measure of rurality: moving beyond threshold measures. Presented at: Selected Paper. 2006. Accessed April 18, 2022. https://ageconsearch.umn.edu/record/21383/files/sp06wa02.pdf | |
dc.identifier.citedreference | Jones J, Zlotorzynska M, Villarino X, Sanchez T. Where is rural? Examining the effect of rural classification method on disparities in HIV and STI testing uptake among men who have sex with men in the United States. AIDS Behav. 2022; 26: 2897 – 2906. | |
dc.identifier.citedreference | Fortenberry JD, McFarlane M, Bleakley A, Bull S, Fishbein M, Grimley DM, et al. Relationships of stigma and shame to gonorrhea and HIV screening. Am J Public Health. 2002; 92 ( 3 ): 378 – 81. | |
dc.identifier.citedreference | Tekeste M, Hull S, Dovidio JF, Safon CB, Blackstock O, Taggart T, et al. Differences in medical mistrust between black and white women: implications for patient–provider communication about PrEP. AIDS Behav. 2019; 23 ( 7 ): 1737 – 48. | |
dc.identifier.citedreference | Bogart LM, Ransome Y, Allen W, Higgins-Biddle M, Ojikutu BO. HIV-related medical mistrust, HIV testing, and HIV risk in the national survey on HIV in the black community. Behav Med. 2019; 45 ( 2 ): 134 – 42. | |
dc.identifier.citedreference | Jacobs EA, Rolle I, Ferrans CE, Whitaker EE, Warnecke RB. Understanding African Americans’ views of the trustworthiness of physicians. J Gen Intern Med. 2006; 21 ( 6 ): 642 – 47. | |
dc.identifier.citedreference | Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017; 29 ( 11 ): 1351 – 8. | |
dc.identifier.citedreference | Sullivan PS, Satcher Johnson A, Pembleton ES, Stephenson R, Justice AC, Althoff KN, et al. Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. Lancet. 2021; 397 ( 10279 ): 1095 – 106. | |
dc.identifier.citedreference | Centers for Disease Control and Prevention. HIV surveillance report. 2019. Accessed April 18, 2022. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html | |
dc.identifier.citedreference | Mansergh G, Kota KK, Stephenson R, Hirshfield S, Sullivan P. Preference for using a variety of future HIV pre-exposure prophylaxis products among men who have sex with men in three US cities. J Int AIDS Soc. 2021; 24 ( 1 ): e25664. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.